Literature DB >> 19546333

Contrast-enhanced breast ultrasonography: imaging features with histopathologic correlation.

He Liu1, Yu-Xin Jiang, Ji-Bin Liu, Qing-Li Zhu, Qiang Sun, Xiao-Yan Chang.   

Abstract

OBJECTIVE: The purpose of this study was to identify histopathologic correlates for the varied appearances of breast masses on contrast-enhanced ultrasonography (CEUS).
METHODS: Contrast-enhanced ultrasonography was performed in 104 patients (age range, 19-86 years) after administration of a sulfur hexafluoride microbubble contrast agent, and enhancement patterns were classified as no enhancement, peripheral enhancement, homogeneous enhancement, regional enhancement, and heterogeneous enhancement. All patients' histologic slides were reviewed and correlated with CEUS findings.
RESULTS: In malignant masses, heterogeneous enhancement corresponded to tumor cell cords or clusters in a variable amount of desmoplastic stroma. Homogeneous enhancement corresponded to hypercellularity in the whole mass, or ductal carcinoma in situ (DCIS) was predominant. Regional enhancement corresponded to a DCIS component. Peripheral enhancement corresponded to a DCIS component, hypercellularity or adenosis at the periphery, and low-degree cellularity, degeneration, fibrosis, or necrosis in the center. No enhancement was present in 1 case of low-grade DCIS. In benign masses, heterogeneous enhancement corresponded to loose cell proliferation in a more sclerotic stroma. Homogeneous enhancement corresponded to diffuse hypercellularity, an inflammatory cell infiltrate, or intraductal papilloma. Regional enhancement corresponded to focal hypercellularity or intraductal papilloma within a dilated duct. No enhancement corresponded to desmoplastic stroma. Peripheral enhancement was shown in 1 case of granulomatous mastitis with an inflammatory infiltrate at the periphery and necrosis in the center.
CONCLUSIONS: Breast mass CEUS findings correlated with histologic features.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19546333     DOI: 10.7863/jum.2009.28.7.911

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  7 in total

1.  Usefulness of contrast-enhanced ultrasonography for intracystic breast tumors: a report of three cases.

Authors:  Kumiko Kato; Hiroko Nogi; Tomoyuki Ohta; Makiko Kamio; Yasuo Toriumi; Norio Nakata; Ken Uchida; Yukio Miyamoto; Hiroshi Takeyama
Journal:  J Med Ultrason (2001)       Date:  2014-02-21       Impact factor: 1.314

2.  Homogeneously enhancing breast lesions on contrast enhanced US: differential diagnosis by conventional and contrast enhanced US findings.

Authors:  Ritsuko Fujimitsu; Mikiko Shimakura; Hiroshi Urakawa; Ayako Morita; Yoshinobu Shinagawa; Keiko Sakamoto; Kengo Yoshimitsu
Journal:  Jpn J Radiol       Date:  2016-05-03       Impact factor: 2.374

Review 3.  Diagnostic accuracy of sonoelastography in different diseases.

Authors:  Iqra Manzoor; Raham Bacha; Syed Amir Gilani
Journal:  J Ultrason       Date:  2018-03-30

4.  The role of contrast-enhanced ultrasound in the diagnosis of malignant non-mass breast lesions and exploration of diagnostic criteria.

Authors:  Fan Zhang; Lifang Jin; Gang Li; Chao Jia; Qiusheng Shi; Lianfang Du; Rong Wu
Journal:  Br J Radiol       Date:  2021-02-09       Impact factor: 3.039

5.  CEUS helps to rerate small breast tumors of BI-RADS category 3 and category 4.

Authors:  Jian-xing Zhang; Li-shan Cai; Ling Chen; Jiu-long Dai; Guang-hui Song
Journal:  Biomed Res Int       Date:  2014-05-25       Impact factor: 3.411

Review 6.  Up-to-date Doppler techniques for breast tumor vascularity: superb microvascular imaging and contrast-enhanced ultrasound.

Authors:  Ah Young Park; Bo Kyoung Seo
Journal:  Ultrasonography       Date:  2017-08-19

7.  Breast non-mass-like lesions on contrast-enhanced ultrasonography: Feature analysis, breast image reporting and data system classification assessment.

Authors:  Ping Xu; Min Yang; Yong Liu; Yan-Ping Li; Hong Zhang; Guang-Rui Shao
Journal:  World J Clin Cases       Date:  2020-02-26       Impact factor: 1.337

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.